6505--Eszopiclone Tablets

The Department of Veterans Affairs National Acquisition Center is soliciting offers for Eszopiclone Tablets in three strengths (1mg, 2mg, and 3mg) supplied in 30-tablet bottles to support VA, Department of Defense, Indian Health Service, Bureau of Prisons, and Federal Health Care Center facilities. The solicitation requires offerors to submit pricing for all line items across a base year plus four one-year option periods, with a mandatory 0.5% Cost Recovery Fee included in proposals. Key contract requirements include electronic submission of offers to specified VA contacts, with proposals due by December 2, 2025 (the original due date of November 20, 2025 has been extended per an amendment). The estimated annual usage totals 39,279 bottles of 1mg tablets, 69,052 bottles of 2mg tablets, and 119,905 bottles of 3mg tablets. One award will be made in aggregate for all line items, and this is a commercial product solicitation under Standard Form 1449.

This solicitation is designated as a small business set-aside with a size standard of 1,300 employees, restricting eligibility to qualifying small business concerns. No incumbent contractor information has been disclosed in the available solicitation documents. While specific award values are not stated in the published materials, the contract value can be estimated based on the substantial annual usage quantities across multiple strengths and the five-year contract period (base plus options). The place of performance encompasses multiple federal facilities across the Veterans Health Administration and other federal healthcare systems nationwide. Interested offerors should review Amendment 0001, posted on November 19, 2025, for updates to the solicitation terms and the extended proposal deadline.